Australia's most trusted
source of pharma news
Posted 27 January 2022 PM
mRNA Covid vaccine developers Pfizer and Moderna are going head-to-head to be the first to make Omicron-specific vaccines available, as data continues to show the variant's ability to evade immunity.
Moderna announced yesterday (Wednesday) that is has begun dosing patients in a clinical trial testing an Omicron-specific booster candidate dubbed mRNA-1273.529.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.